Category Archives: Patent Eligible Subject Matter

Enzo Biochem V. Applera Corp. – When “Words Can Hurt You”

Posted on March 19, 2015 by Warren Woessner

On March 16, 2015 (Appeal no. 2014-1321), the Fed. Cir. reversed the district court’s construction of a claim term relating to the scope of “A,” a moiety capable of direct or indirect signaling that is attached by a linker to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | Leave a comment

Novartis Wins Landmark Biosimilar Approval

Posted on March 9, 2015 by Warren Woessner

Novartis Navigates The FDA-ACA Maze – Gets Approval For Generic Neuprogen. Amgen will soon find itself in a price war with Sandoz – a Novartis company – as it tries to maintain its share of the market for Neuprogen (filgraslim). … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Pacing Technologies v. Garmin – D&D Explained

Posted on February 20, 2015 by Warren Woessner

In this decision—No. 2014-1396 (Fed. Cir., Feb. 18, 2015)—the court affirmed a grant of summary judgment (a copy can be found at the end of this post) that Garmin’s exercise products do not infringe the claims of Pacing’s US Pat. … Continue reading →

Posted in Claim Interpretation, Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

“Precision Medicine” Initiative Leaves Patents “Lost in Space”

Posted on February 18, 2015 by Warren Woessner

On January 30th, the White House released a press release expanding upon President Obama’s mention of “precision medicine” in his State of the Union Address. Not surprisingly, the details are pretty much what we who are involved in various aspects … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , | Leave a comment